Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)

Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)

Abstract Backgrounds/Aim Recent studies have shown that the addition of sodium-glucose co-transporter 2 (SGLT2) inhibitors gradually reduces the estimated fluid volume parameters in a broad range of patient populations, suggesting that this mediates the clinical benefits of SGLT2 inhibitors in preve...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Takumi Imai, Shigeru Toyoda, Kazuhiro Sugimoto, Ruka Yoshida, Machi Furuta, Koichi Node, the PROTECT Investigators
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Estimated fluid volume
Sodium-glucose co-transporter 2 inhibitor
Ipragliflozin
Type 2 diabetes mellitus
N-terminal pro-brain natriuretic peptide
Online Access:https://doi.org/10.1186/s13098-023-01129-3

Internet

https://doi.org/10.1186/s13098-023-01129-3

Similar Items